A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

NCT07357415 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults who have obesity or overweight but do not have type 2 diabetes to see how it affects their body weight.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 600 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-01 · est. completion 2028-11

Where 35 sites · Argentina, Canada, United States

What this study is testing ClinicalTrials.gov NCT07357415 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07357415 ↗